• colebunn
    Opinions on why investors don't seem to care about $BLUE acquiring Pregenen? Seems exciting/promising for $BLUE believers
    Reply (2)
    • Blackbeard: Hard to move needle when products are still many years from actual sale. Continued proof of concept/safety studies will affect stock more.
    • colebunn: Absolutely, but this technology should improve the delivery efficiency of their products - which is often an issue in gene therapy